United Therapeutics starts litigation with FDA for allowing Liquidia's drug application
Feb 21 (Reuters) - United Therapeutics UTHR.O said on Wednesday it has commenced litigation with the U.S. FDA for allowing an application for a drug by Liquidia Corp LQDA.O to treat a type of blood vessel disorder. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli) ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug